Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: What causes Remeron Weight gain

Posted by allisonm on July 10, 2000, at 21:19:58

In reply to Re: What causes Remeron Weight gain, posted by allisonm on July 10, 2000, at 19:47:41

And then there's this from Organon... I guess I am in the 17% group of those with weight gain.
A.

PRECAUTIONS

General

Somnolence: In U. S. controlled studies, somnolence was reported in 54% of patients treated with REMERON® (mirtazapine)
Tablets, compared to 18% for placebo and 60% for amitriptyline. In these studies, somnolence resulted in discontinuation for
10.4% of REMERON® treated patients, compared to 2.2% for placebo. It is unclear whether or not tolerance develops to the
somnolent effects of REMERON®. Because of REMERON® ’s potentially significant effects on impairment of performance,
patients should be cautioned about engaging in activities requiring alertness until they have been able to assess the drug’s effect on
their own psychomotor performance (see PATIENT INFORMATION).

Dizziness: In U.S. controlled studies, dizziness was reported in 7% of patients treated with REMERON®, compared to 3% for
placebo and 14% for amitriptyline. It is unclear whether or not tolerance develops to the dizziness observed in association with the
use of REMERON®.

Increased Appetite/Weight Gain: In U. S. controlled studies, appetite increase was reported in 17% of patients treated with
REMERON®, compared to 2% for placebo and 6% for amitriptyline. In these same trials, weight gain of >7% of b.d. weight was
reported in 7.5% of patients treated with mirtazapine, compared to 0% for placebo and 5.9% for amitriptyline. In a p.o. of
premarketing U.S. studies, including many patients for long-term, open label treatment, 8% of patients receiving REMERON®
discontinued for weight gain.

Cholesterol/Triglycerides: In U.S. controlled studies, nonfasting cholesterol increases to 20% above the upper limits of normal
were observed in 15% of patients treated with REMERON®, compared to 7% for placebo and 8% for amitriptyline. In these same
studies, nonfasting triglyceride increases to 500 mg/dL were observed in 6% of patients treated with mirtazapine, compared to 3%
for placebo and 3% for amitriptyline.



Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:allisonm thread:39864
URL: http://www.dr-bob.org/babble/20000708/msgs/40012.html